[ExpertScie]

The good news in the treatment of Parkinson’s disease is that the vaccines for Parkinson’s disease had entered successfully into first phase of clinical trials & hopefully will be in market soon upon passing remaining two clinical trials. These are therapeutic vaccines for treatment of Parkinson’s disease, chronic human disorders including neurological condition and even cancers.
The underlying molecular cause of the disease is a protein called alpha-synuclein. Normally this protein is found throughout the neocortex, hippocampus, substantia nigra, thalamus and cerebellum, although its precise function remains unknown. Importantly, this protein is very unusual and it does not fold up like the majority of proteins. Its unfolded appearance means that it is particularly susceptible to getting tangled up and forms protein aggregates within brain cells, thus affecting cell death occur. The formation of protein aggregates results in brain disorders, including Alzheimer’s disease and Creutzfeld-Jacob disease.
Discovering the protein aggregates role in brain diseases, therapeutic vaccination might therefore represent a promising future treatment for several neurological conditions. Therefore these vaccines target alpha-synuclein protein and currently in trials, namely PD01A.
The results are expected in July 2014 and the funding Michael J. Fox Foundation and other regulatory authorities will assess the safety of the vaccine in both men and women with Parkinson’s disease.
Another research in this field carried out the first genome wide evaluation of variants of gene linked to Parkinson’s disease. And the initial results had shown that people with genetic variants in gene HLA, SNCA, RIT2 had higher than average risk of Parkinson’s disease. This invention is further helping in treatment of Parkinson’s disease.